NCT05605535 2025-07-11
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
CanariaBio Inc.
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT05335993 2025-07-10
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
CanariaBio Inc.
Phase 2 Active not recruiting
NCT04498117 2025-07-09
FLORA-5
CanariaBio Inc.
Phase 3 Active not recruiting
NCT04938583 2023-10-17
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Unknown
NCT03162562 2020-12-22
The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer
CanariaBio Inc.
Phase 1 Terminated
NCT01616303 2020-09-14
A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer
Quest PharmaTech Inc.
Phase 2 Completed
NCT00551265 2017-07-14
Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy
GOG Foundation
Phase NA Withdrawn
NCT00003634 2013-11-06
Monoclonal Antibody Therapy in Treating Patients With Residual Disease From Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Following Surgery and Chemotherapy
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00004064 2013-11-06
Monoclonal Antibody Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00034138 2007-12-18
A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma
Unither Pharmaceuticals
Phase 1/2 Terminated
NCT00050375 2007-12-18
Clinical Trial for Ovarian Cancer (OvaRex®)
Unither Pharmaceuticals
Phase 3 Terminated
NCT00086632 2007-12-18
Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment
Unither Pharmaceuticals
Phase 2 Terminated